World's Best Scientists 2026 revealed!
Meredith M. Regan

Meredith M. Regan

D-Index & Metrics

Medicine

D-Index
103
Citations
49107
World Ranking
7234
National Ranking
3793

Overview

Meredith M. Regan is affiliated with Harvard University in the United States and has made substantial contributions to the fields of medicine and biochemistry, genetics, and molecular biology. Their research is primarily focused on oncology, pulmonary and respiratory medicine, and cancer research. The subfields where they have a significant presence include oncology, pulmonary and respiratory medicine, cancer research, genetics, and radiology, nuclear medicine, and imaging.

The main research topics of Meredith M. Regan revolve around breast cancer treatment studies, advanced breast cancer therapies, cancer genomics and diagnostics, HER2/EGFR in cancer research, cancer immunotherapy and biomarkers, estrogen and related hormone effects, and renal cell carcinoma treatment.

Among the recent papers authored by Meredith M. Regan are:

  • Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update, 2020, Journal of Clinical Oncology
  • Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline, 2021, Journal of Clinical Oncology
  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021, 2021, Annals of Oncology
  • Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2023, Annals of Oncology
  • Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update, 2020, Archives of Pathology & Laboratory Medicine

Meredith M. Regan frequently collaborates with other researchers. Some of the most frequent co-authors include:

  • Marco Colleoni
  • Sherene Loi
  • Prudence A. Francis
  • Giuseppe Viale
  • Sara M. Tolaney

Their publications are commonly found in several key scientific journals, including:

  • Journal of Clinical Oncology
  • Cancer Research
  • Annals of Oncology
  • Clinical Cancer Research
  • Journal for ImmunoTherapy of Cancer

Best Publications

  • Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

    Mitch Dowsett;Torsten O. Nielsen;Roger A’Hern;John Bartlett

  • Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Mark A. Warren

  • Effect of sleep loss on C-Reactive protein, an inflammatory marker of cardiovascular risk ☆

    Hans K Meier-Ewert;Paul M Ridker;Nader Rifai;Meredith M Regan

  • Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

    Viviana Galimberti;Bernard F. Cole;Bernard F. Cole;Stefano Zurrida;Giuseppe Viale;Giuseppe Viale

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer

    Qianben Wang;Wei Li;Yong Zhang;Xin Yuan

  • Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

    David F. McDermott;Meredith M. Regan;Joseph I. Clark;Lawrence E. Flaherty

  • External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Lauren C. Harshman

  • Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.

    Kimberly H. Allison;M. Elizabeth H. Hammond;Mitchell Dowsett;Shannon E. McKernin

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

    Olivia Pagani;Meredith M. Regan;Barbara A. Walley;Gini F. Fleming

  • Adjuvant ovarian suppression in premenopausal breast cancer

    Prudence A. Francis;Prudence A. Francis;Meredith M. Regan;Gini F. Fleming;István Láng

  • The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer.

    Mark M. Pomerantz;Nasim Ahmadiyeh;Nasim Ahmadiyeh;Li Jia;Paula Herman

  • Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

    Henning Mouridsen;Anita Giobbie-Hurder;Aron Goldhirsch;Beat Thürlimann

  • Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

    Larissa A. Korde;Mark R. Somerfield;Lisa A. Carey;Jennie R. Crews

  • Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

    P. A. Francis;P. A. Francis;O. Pagani;G. F. Fleming;B. A. Walley

  • Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98

    Giuseppe Viale;Meredith M. Regan;Eugenio Maiorano;Mauro G. Mastropasqua

  • Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019

    H.J. Burstein;G. Curigliano;S. Loibl;P. Dubsky

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

    H J Burstein;G Curigliano;B Thürlimann;W P Weber

  • Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer

    Michael Atkins;Meredith Regan;David McDermott;James Mier

Frequent Co-Authors

Richard D. Gelber
Richard D. Gelber Harvard University
Giuseppe Viale
Giuseppe Viale University of Milan
Alan S. Coates
Alan S. Coates University of Sydney
Marco Colleoni
Marco Colleoni European Institute of Oncology
Aron Goldhirsch
Aron Goldhirsch European Institute of Oncology
Karen N. Price
Karen N. Price Frontier Science Foundation
William Oh
William Oh Icahn School of Medicine at Mount Sinai
Philip W. Kantoff
Philip W. Kantoff Memorial Sloan Kettering Cancer Center
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Michael B. Atkins
Michael B. Atkins Georgetown University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine opens up diverse online pathways beyond becoming a physician. Many students look for flexible degree options that fit their schedule and career goals. For example, aspiring nurse practitioners without prior nursing experience can now access direct entry np programs for non nurses online. These programs streamline education, helping non-nursing degree holders transition into advanced practice roles efficiently.

If you’re interested in starting your nursing journey sooner, consider online adn programs (Associate Degree in Nursing). These programs often have more flexible admission policies and faster completion times compared to traditional bachelor’s degrees.

For those drawn to the administrative side of healthcare, taking medical coding and billing classes online with financial aid can provide a strong foundation for work in medical offices or hospitals—with support for eligible students.

Additionally, some institutions offer lpn school without teas test requirements, easing the application process for those who may be concerned about standardized test barriers.

Best Scientists Citing Meredith M. Regan

Trending Scientists